295 results on '"Gassó, Patricia"'
Search Results
2. Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls
3. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine
4. Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk
5. Epigenetic age deacceleration in youth at familial risk for schizophrenia and bipolar disorder
6. The polygenic basis of relapse after a first episode of schizophrenia
7. Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
8. Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia.
9. The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study
10. Gene expression study in monocytes: evidence of inflammatory dysregulation in early-onset obsessive-compulsive disorder
11. Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients
12. The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model
13. The role of psychosis and clozapine load in excessive checking in treatment-resistant schizophrenia: longitudinal observational study
14. Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms
15. Altered frequencies of Th17 and Treg cells in children and adolescents with obsessive-compulsive disorder
16. Genetic variability in the serotoninergic system and age of onset in anorexia nervosa and obsessive-compulsive disorder
17. Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia
18. Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients
19. Modelling gene-environment interaction in first episodes of psychosis
20. Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine
21. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients
22. Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine
23. Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders
24. Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
25. Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive–compulsive disorder
26. Neurotoxic/Neuroprotective Effects of Clozapine and the Positive Allosteric Modulator of mGluR2 JNJ-46356479 in Human Neuroblastoma Cell Cultures
27. The Effect of Clozapine and Novel Glutamate Modulator JNJ-46356479 on Nitrosative Stress in a Postnatal Murine Ketamine Model of Schizophrenia
28. Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia
29. Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients
30. Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
31. Common genetic background in anorexia nervosa and obsessive compulsive disorder: Preliminary results from an association study
32. Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies
33. Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode.
34. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells
35. Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
36. Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients
37. Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort; 35659654
38. Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia
39. ARVCF single marker and haplotypic association with schizophrenia
40. TH68. METABOLIC POLYGENIC RISK SCORES EFFECT ON ANTIPSYCHOTIC-INDUCED METABOLIC DYSREGULATION: A LONGITUDINAL STUDY IN A FIRST EPISODE PSYCHOSIS COHORT
41. Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data
42. Polimorfismos genéticos en la catecol-O-metiltransferasa y riesgo de esquizofrenia en población española
43. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders
44. Integrative DNA Methylation and Gene Expression Analysis of Cognitive Behavioral Therapy Response in Children and Adolescents with Obsessive-Compulsive Disorder; a Pilot Study
45. 5.40 Exploring the Genetic Architecture of Early-Onset OCD: Effect of Autoimmune and Inflammatory Polygenic Risk Scores
46. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics
47. DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results
48. Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial
49. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial
50. Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.